Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

Annals of Neurology

Volumn 39, Issue 1, 1996, Pages 6-16

  Miller, D H ^a   Albert, P S ^b   Barkhof, F ^c   Francis, G ^d   Frank, J A ^b   Hodgkinson, S ^e   Lublin, F D ^f   Paty, D W ^g   Reingold, S C ^h   Simon, J ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MCGILL UNIVERSITY   (Canada)

^e LIVERPOOL HOSPITAL   (Australia)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h National Multiple Sclerosis Society   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; N ACETYLASPARTIC ACID;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMYELINATION; DIAGNOSTIC VALUE; DISABILITY; HUMAN; MAGNETISM; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSE; TREATMENT OUTCOME;

CLINICAL TRIALS; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 9044245703     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390104     Document Type: Article

References (93)

1. Noseworthy JH, Van der Voort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-975
2. Noseworthy JH, Ebers GC, Vandervoort MK, et al. The impact of blinding on the results of a randomized, placebocontrolled multiple sclerosis clinical trial. Neurology 1994;44: 16-20
3. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerred Action Guidelines. J Neurol Neurosurg Psychiatry 1991; 54:683-688
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-661
5. Pary DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
6. The IFNB Study Group, University of British Columbia MS/ MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. Neurology 1995;45:1277-1285
7. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Out-comes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47
8. Willoughby EW, Grochowski E, Li DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49
9. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
10. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in multiple sclerosis. Ann Neurol 1993;34:661-669
11. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555
12. Barkhof F, Scheltens P, Frequin STFM, et al. Relapsing-remit-ting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. Am J Radiol 1992;159:1041-1047
13. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094
14. Stone LA, Frank JA, Albert PS, et al. The effect of beta interferon on blood brain barrier disruptions demonstrated by contrast enhanced MRI in relapsing remitting multiple sclerosis. Ann Neurol 1995;37:611-619
15. Thorpe JW, Halpin SF, MacManus DG, et al. A comparison between fast spin echo and conventional spin echo in the detection of multiple sclerosis lesions. Neuroradiology 1994;36: 388-392
16. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadoliniumenhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology (in press)
17. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (in press)
18. Ormerod IEC, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. Brain 1987;110:1579-1616
19. Martinelli V, Comi G, Filippi M, et al. Paraclinical tests in acute onset optic neuritis: basal data and results of a short follow up study. Acta Neurol Scand 1991;84:231-236
20. Frederiksen JL, Larsson HBW, Olesen J, Henriksen O. Magnetic resonance imaging of the brain in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 1991;83: 343-350
21. Lee KH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991;41:657-660
22. Jacobs L, Munschauer FE, Kaba SE. Clinical and magnetic resonance imaging in optic neuritis. Neurology 1991;41:15-19
23. Ford B, Tampieri D, Francis G. Long term follow up of acute transverse partial myelopathy. Neurology 1992;42:250-252
24. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 1993;116:135-146
25. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769
26. Campi A, Filippi M, Comi G, er al. Acute transverse myelopathy: spinal and cranial MR study with clinical follow-up. AJNR 1995;16:115-123
27. Tas MW, Barkhof F, van Walderveen MAAA, et al. The effect of gadolinium on the sensitivity and specificity of MR imaging in the initial diagnosis of multiple sclerosis. AJNR 1995;16: 259-264
28. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44: 635-641
29. Barkhof F, Filippi M, Horsfield MA, et al. Towards specific magnetic resonance imaging criteria in the early diagnosis of multiple sclerosis. Neurology 1995;45(suppl 4):A398
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983;33:1444-1452
31. Koopmans R, Li DKB, Grochowski E, et al. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol 1989;25:74-81
32. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990;300:631-634
33. Dousset V, Grossman R, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterisation with magnetization transfer imaging. Radiology 1992;182: 483-491
34. Barbosa S, Blumhardt LD, Roberts N, et al. Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. Magn Reson Imaging 1994;12:33-42
35. 1H spectroscopic imaging. Ann Neurol 1994;36:157-165
36. Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 1988;38:175-179
37. Youl BD, Turano G, Miller DH, et al. The pathophysiology of optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991;114: 2437-2450
38. Lee DH, Simon JH, Szumowski J, et al. Optic neuritis and orbital lesions: lipid suppressed chemical shift imaging. Radiology 1991;179:543-546
39. Atlas SW, Grossman RI, Savino PJ, et al. Internuclear ophthalmoplegia: MR-anatomic correlation. AJNR 1987;8:243-247
40. Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39:161-166
41. Ron MA, Callanan MM, Warrington EK. Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. Psychol Med 1991;21:59-68
42. Swirsky-Sachetti T, Mitchell DR, Seward J, et al. Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology 1992;42:1291-1295
43. Arnett PA, Rao SM, Bernardin L, et al. Relationship between frontal lobe and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology 1994;44:420-425
44. Filippi M, Campi A, Mammi S, et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;58:31-37
45. Kidd D, Thompson AJ, Kendall BE, et al. Benign form of multiple sclerosis: MRI evidence for less frequent and less in flammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-1072
46. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67
47. van Walderveen MAA, Barkhof F, Hommes OR, et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/TE ("T1-weighted") spin-echo images. Neurology 1995;45:1684-1690
48. Grossman RI, Gonzales-Scarano F, Atlas SW, et al. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;169:117-122
49. Thompson AJ, Miller D, Youl B, et al. Serial gadoliniumehhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63
50. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489
51. Stone LA, Smith ME, Albert PS, et al. Blood brain barrier disruption as measured by contrast enhanced MRI in patients with mild relapsing remitting multiple sclerosis: relationship to course, gender and age. Neurology 1995;45:1122-1126
52. Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36:S86-S90
53. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124
54. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis, a follow up study. Neurology 1995;45:255-260
55. Filippi M, Barker GJ, Horsfield MA, et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neurol 1994;241:246-251
56. Matthews P, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic chatacterization of plaques in multiple sclerosis. Neurology 1991;41:1251
57. Davie CA, Barker GJ, Webb S, et al. Proton magnetic resonance spectroscopy (MRS) study of cerebellar dysfunction in multiple sclerosis. J Neurol 1994;341(suppl 1):S151
58. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-2637
59. Hiehle JF, Grossman RI, Ramer KN, et al. Magnetization transfer effect in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and non-enhanced T1-weighted images. AJNR 1995;16:69-77
60. Dousset V, Brochet B, Vital A, et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer AJNR 1995;16:225-231
61. Albert PS, McFarland HF, Smith ME, Frank JA. Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. Stat Med 1994;13:453-466
62. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and cross-over designs. J Neurol Sci 1994;122:6-14
63. McFarland HF, Frank JA, Albert PS, et al. Using gadoliniumenhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
64. Berry DA. Basic principles in designing and analysing clinical studies. In: Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker, 1990:1-55
65. Moreau X, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301
66. Simon JH, Jacobs L, Cookfair D, et al. The natural history of MS based on an annual MR snapshot: results from the MSCRG study of intramuscular recombinant interferon beta-1a. Neurology 1995;45(suppl 4):A418
67. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing remitting multiple scletosis. Neurology 1995;45:1808-1814
68. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40:1764-1769
69. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58
70. Arnold DL, Reiss GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82
71. Larsson HBW, Thomsen C, Frederiksen J, et al. In vivo magnetic resonance diffusion measurement in the brain of patients with multiple sclerosis. Magn Reson Imaging 1992;10:7-12
72. MacKay A, Whittal K, Adler J, et al. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994;31:673-677
73. Barnes D, Munro PMG, Youl BD, et al. The longstanding lesion in multiple sclerosis. Brain 1991;114:1271-1280
74. Poser CM, Paty DW, Schcinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
75. Thomas DJ, Pennock JM, Hajnal JV, et al. Magnetic resonance imaging of spinal cord in multiple sclerosis by fluid attenuated inversion recovery. Lancet 1993;341:593-594
76. Rydberg JN, Hammond CA, Grimm RC, et al. Initial experience in MR imaging of the brain with a fast fluid-attenuated inversion-recovery pulse sequence. Radiology 1994;193:173-180
77. Finelli DA, Hurst GC, Karsman BA, et al. Use of magnetization transfer for improved contrast on gradient-echo images of the cervical spine. Radiology 1994;193:165-171
78. Mathews VP, King JC, Elster AD, Hamilton CA. Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging. Radiology 1994;190: 547-552
79. Finelli DA, Hurst GC, Gullapali RP, Belon EM. Improved contrast of enhancing brain lesions on post gadolinium, T1-weighted spin echo images with use of magnetization transfer. Radiology 1994;190:553-559
80. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (in press)
81. Duyn JH, Gillen J, Sobering G, et al. Multislice proton spectroscopic imaging of the human brain. Radiology 1993;188: 277-282
82. Kruse B, Barker PB, van Zijl PCM, et al. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994;36:595-608
83. Kastrukoff LF, Oger JJF, Hashimoto SA, et al. Systemic lymphoblastoid Interferon therapy in chronic progressive multiple sclerosis. Neurology 1990;40:479-486
84. Wicks DAG, Tofts PS, Miller DH, et al. Volume measurement of multiple sclerosis lesions with magnetic resonance images. Neuroradiology 1992;34:475-479
85. Filippi M, Horsfield MA, Baratti C, et al. Inter-rater variability of brain MRI lesion volume measurements in multiple scleiosis. Proc Soc Magn Reson 1994;1:167 (Abstract)
86. Grimaud J, Lai M, Thorpe JW, et al. Evaluation of computer-assisted quantification of MS lesions in cranial MRI. J Neurol Neurosurg Psychiatry 1995;58:215 (Abstract)
87. Cline HE, Lorensen WE, Kikinis R, Jolesz F. Three-dimensional segmentation of MR images of the head using probability and connectivity. J Comput Assist Tomogr 1990;14:1037-1045
88. Jackson EF, Narayana PA, Wolinsky JS, Doyle TJ. Accuracy and reproducibility in volumetric analysis of multiple sclerosis lesions. J Comput Assist Tomogr 1993;17:200-205
89. Ross Mitchell J, Karlick SJ, Lee DH, Fenster A. Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brain. J Magn Reson Imaging 1994;4:197-208
90. Goodkin DE, Ross JS, VanderBrug Medendorp S, et al. MRI lesion enlargement in multiple sclerosis: disease-related activity, chance occurrence, or measurement artifact. Arch Neurol 1992;49:261-264
91. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994;18:192-205
92. Simon JH, Holtas SL, Schiffer RB, et al. Corpus callosum and subcallosal periventricular lesions in multiple sclerosis. Radiology 1986;160-363-367
93. Truyen L, Gheuens J, Van de Vyver FE, et al. Improved correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by use of an extensive standardized imaging protocol. J Neurol Sci 1990;96:173-182